Tag: Atypical antipsychotic

  • Quetiapine

    Atypical antipsychotic

    A dibenzothiazepine atypical antipsychotic with broad receptor binding; the active metabolite norquetiapine is a NET inhibitor contributing to antidepressant efficacy.

    Abstract

    Quetiapine (2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-piperazin-1-yl)ethoxy]ethanol; CAS 111974-69-7; molecular formula C21H25N3O2S; molecular weight 383.51) is a dibenzothiazepine atypical antipsychotic developed at AstraZeneca and approved by the FDA in 1997 under the trade name Seroquel. The receptor profile is broad: D2 (Ki approximately 770 nM, the weakest of the antipsychotic class), 5-HT2A (Ki approximately 295 nM), H1 (Ki approximately 11 nM), alpha-1 (Ki approximately 22 nM), 5-HT1A partial agonism. The active metabolite norquetiapine (formed via CYP3A4) is a potent NET inhibitor (Ki approximately 35 nM) and a 5-HT2C antagonist, contributing to antidepressant efficacy and supporting the FDA-approved adjunctive use in major depressive disorder. Plasma half-life is 6 to 7 hours; metabolism is via CYP3A4. Approved for schizophrenia, bipolar I disorder (mania, depression, maintenance), and adjunctive in MDD. Off-label use as a hypnotic at 25 to 100 mg is widespread despite a poor efficacy-to-side-effect ratio for that indication. Used as a reference broad-spectrum atypical antipsychotic in mechanism studies.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Olanzapine

    Atypical antipsychotic

    A thienobenzodiazepine atypical antipsychotic structurally and mechanistically related to clozapine, without the agranulocytosis risk.

    Abstract

    Olanzapine (2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; CAS 132539-06-1; molecular formula C17H20N4S; molecular weight 312.43) is a thienobenzodiazepine atypical antipsychotic developed at Eli Lilly and approved by the FDA in 1996 under the trade name Zyprexa. The receptor profile is closely related to clozapine: D2 (Ki approximately 11 nM, higher affinity than clozapine), 5-HT2A (Ki approximately 4 nM), H1 (Ki approximately 0.087 nM, among the most potent in clinical use), alpha-1, muscarinic, 5-HT2C, 5-HT3, 5-HT6, 5-HT7. The structural difference from clozapine eliminates the agranulocytosis liability while preserving the broad-spectrum atypical pharmacology. Plasma half-life is 21 to 54 hours; metabolism is via CYP1A2 and direct glucuronidation. The compound carries the highest metabolic risk profile of any commonly used antipsychotic: dyslipidemia, weight gain (mean 4 to 12 kg over 12 weeks), and incident type 2 diabetes are well-documented, attributed to combined H1 and 5-HT2C antagonism. Approved for schizophrenia, bipolar I disorder, and treatment-resistant depression in combination with fluoxetine (Symbyax). Used as a reference broad-spectrum atypical antipsychotic.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Risperidone

    Atypical antipsychotic

    A benzisoxazole atypical antipsychotic; the most prescribed atypical worldwide and the prototype combined D2 / 5-HT2A antagonist.

    Abstract

    Risperidone (3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one; CAS 106266-06-2; molecular formula C23H27FN4O2; molecular weight 410.49) is a benzisoxazole atypical antipsychotic developed at Janssen and approved by the FDA in 1993 under the trade name Risperdal. The receptor profile is the prototype combined D2/5-HT2A antagonist: D2 (Ki approximately 4 nM), 5-HT2A (Ki approximately 0.16 nM, ratio approximately 25:1 favoring 5-HT2A), with secondary alpha-1, alpha-2, and H1 antagonism. The active metabolite 9-hydroxyrisperidone (paliperidone, marketed as Invega) carries similar receptor profile and contributes substantially to steady-state activity. Risperidone is the most prescribed atypical antipsychotic worldwide. Plasma half-life is 3 hours for parent, 24 hours for paliperidone metabolite. Long-acting injectables (Risperdal Consta, Perseris) provide biweekly or monthly administration. Approved for schizophrenia, bipolar mania, autism-associated irritability. Used as the canonical D2/5-HT2A reference atypical.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.